Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Operating Expenses: 2013-2024

Historic Operating Expenses for Rocket Pharmaceuticals (RCKT) over the last 12 years, with Dec 2024 value amounting to $273.2 million.

  • Rocket Pharmaceuticals' Operating Expenses fell 24.74% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.5 million, marking a year-over-year decrease of 8.51%. This contributed to the annual value of $273.2 million for FY2024, which is 5.22% up from last year.
  • As of FY2024, Rocket Pharmaceuticals' Operating Expenses stood at $273.2 million, which was up 5.22% from $259.7 million recorded in FY2023.
  • Rocket Pharmaceuticals' 5-year Operating Expenses high stood at $273.2 million for FY2024, and its period low was $134.3 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $259.7 million (2023), whereas its average is $252.4 million.
  • Data for Rocket Pharmaceuticals' Operating Expenses shows a peak YoY soared of 76.36% (in 2020) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Operating Expenses (Yearly) stood at $134.3 million in 2020, then rose by 24.53% to $167.2 million in 2021, then soared by 34.14% to $224.3 million in 2022, then rose by 15.74% to $259.7 million in 2023, then climbed by 5.22% to $273.2 million in 2024.